Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial

Journal:
The Lancet Neurology
Published:
DOI:
10.1016/s1474-4422(25)00386-2
Affiliations:
4
Authors:
17
Go to article
Institutions Authors Share
University of Cambridge, United Kingdom (UK)
13.000000
13.000000
 0.76
Addenbrooke's Hospital, United Kingdom (UK)
3.000000
 0.18
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK)
1.000000
 0.06
Interested in Neurosciences?